Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered ...

Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

which evaluated the co-administration of melanocortin 4 receptor or MC4R agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide or GLP-1/GIP tirzepatide arm ...

Mounjaro (Terzepatide) is a dual GLP-1/GIP (Gastric Inhibitory Peptide) receptor agonist, which may offer better blood sugar control and enhanced weight loss compared to traditional GLP-1 agonists.

The candidate at the center of the deal, dubbed UBT251, is a triple agonist for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon. Wegovy already inhibits GLP-1 ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn.

UBT251, a so-called “triple G” agonist, targets GLP-1, gastric inhibitory polypeptide (GIP) and glucagon. For comparison, Wegovy inhibits GLP-1 while Eli Lilly’s competitor Zepbound ...

For instance, glucagon-like peptide-1 (GLP-1 ... including tirzepatide (Mounjaro; Eli Lilly), a GLP-1/gastric inhibitory polypeptide (GIP) dual receptor agonist, and retatrutide, a GLP-1/GIP ...